Candel Therapeutics Shares Are Up Today: What's Going On?
Candel Therapeutics Shares Are Up Today: What's Going On?
The study involved a median follow-up of 50.3 months and identified no new safety concerns. Adverse events were consistent with prior trials and were mostly mild or moderate flu-like symptoms.Candel Therapeutics, Inc. (NASDAQ:CADL) shares are trading higher Thursday potentially driven by continued momentum following the company's announcement of positive phase 3 trial results for its CAN-2409 viral immunotherapy in prostate cancer patients. Here's what you need to know.
Candel Therapeutics, Inc.（納斯達克：CADL）股票在週四上漲，可能受公司宣佈前列腺癌患者CAN-2409病毒免疫療法的積極三期試驗結果的持續勢頭推動。以下是您需要知道的內容。
What To Know: The phase 3 trial focused on intermediate-to-high-risk, localized prostate cancer and showed that CAN-2409, combined with valacyclovir and standard care, significantly improved disease-free survival compared to standard care alone. The trial met its primary endpoint, demonstrating statistical significance in disease-free survival, with a hazard ratio of 0.7 and a p-value of 0.0155.
要知道的是：這項三期試驗專注於中到高風險的局部前列腺癌，結果顯示CAN-2409與伐昔洛韋和標準護理聯合使用，與單獨的標準護理相比，顯著提高了無病生存期。該試驗達到了其主要終點，在無病生存期上顯示出統計學意義，風險比爲0.7，p值爲0.0155。
At 54 months, the CAN-2409 treatment arm showed a 14.5% relative improvement in disease-free survival compared to the control arm. The benefit was observed regardless of whether patients received short-term androgen deprivation therapy. Additional findings highlighted CAN-2409's significant effects on prostate-specific cancer outcomes, including higher rates of prostate-specific antigen nadir and pathological complete responses.
在54個月時，CAN-2409治療組相比對照組顯示出無病生存期相對改善了14.5%。無論患者是否接受短期雄激素抑制治療，都觀察到了這一益處。額外發現強調了CAN-2409對前列腺癌特定結果的顯著影響，包括前列腺特異性抗原的最低值和病理完全應答率更高。
The study involved a median follow-up of 50.3 months and identified no new safety concerns. Adverse events were consistent with prior trials and were mostly mild or moderate flu-like symptoms.
該研究的中位隨訪時間爲50.3個月，沒有發現新的安全隱患。副作用與之前的試驗一致，主要爲輕度或中度流感樣症狀。
The company also shared data from a phase 2 trial in low-to-intermediate risk localized prostate cancer patients undergoing active surveillance. Although this trial showed numerical improvements in outcomes like time to radical treatment and negative biopsies, the results were not statistically significant.
該公司還分享了對低至中等風險局部前列腺癌患者進行主動監測的二期試驗數據。儘管該試驗顯示出在放射治療時間和陰性活檢等結果上的數值改善，但結果並沒有統計學意義。
Candel's stock surged over 100% following the announcement on Wednesday and today's continued gains potentially reflect ongoing interest in the trial results and their potential implications for prostate cancer treatment.
在週三宣佈後，Candel的股價上漲超過100%，而今天的持續增長可能反映出市場對試驗結果及其對前列腺癌治療潛在影響的持續興趣。
CADL Price Action: Candel Therapeutics shares were up 32.3% at $10.29 at the time of writing, according to Benzinga Pro.
CADL價格動態：根據Benzinga Pro的數據，Candel Therapeutics的股票在撰寫時上漲了32.3%，報$10.29。
- Archer Aviation Teams Up with Anduril For Defense VTOL, Bolsters Arsenal With $430M Raise
- Archer航空與Anduril合作開發軍工股VTOL，融資43000萬美元增強武器庫
Image Via SHutterstock.
圖片來源於Shutterstock。
譯文內容由第三人軟體翻譯。
